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Abstract
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in
two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-
experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented.
Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs)
with viral load (VL) ‡400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in
AMBER, and HIV-1 proviral DNA from baseline samples (VL <50 copies/mL) in EMERALD. Through week 48
across both studies, no darunavir, primary PI, or tenofovir resistance-associated mutations (RAMs) were observed
in HIV-1 viruses of 1,125 participants receiving D/C/F/TAF or 629 receiving boosted darunavir plus emtricitabine/
tenofovir-disoproxil-fumarate. In AMBER, the nucleos(t)ide analog reverse transcriptase inhibitor (N(t)RTI) RAM
M184I/V was identified in HIV-1 of one participant during D/C/F/TAF treatment. M184V was detected pretreat-
ment as a minority variant (9%). In EMERALD, in participants with prior VF and genoarchive data (N= 140; 98
D/C/F/TAF and 42 control), 4% had viruses with darunavir RAMs, 38% with emtricitabine RAMs, mainly at
position 184 (41% not fully susceptible to emtricitabine), 4% with tenofovir RAMs, and 21%‡ 3 thymidine analog-
associated mutations (24% not fully susceptible to tenofovir) detected at screening. All achieved VL <50 copies/mL
at week 48 or prior discontinuation. D/C/F/TAF has a high genetic barrier to resistance; no darunavir, primary PI, or
tenofovir RAMs were observed through 48 weeks in AMBER and EMERALD. Only one postbaseline M184I/V
RAM was observed in HIV-1 of an AMBER participant. In EMERALD, baseline archived RAMs to darunavir,
emtricitabine, and tenofovir in participants with prior VF did not preclude virologic response.
Keywords: darunavir/cobicistat/emtricitabine/TAF, single-tablet regimen, resistance, efficacy, deep sequencing,
archived RAMs
Introduction
W ith the increasing choice of combination HIV-1antiretroviral therapy (ART) regimens with similar
high efficacy, selection of an ART regimen is frequently
based on safety, tolerability, convenience, and genetic barrier
to ART resistance.1–3 Understanding the resistance profile of
the component antiretrovirals and the potential for emer-
gence of resistance-associated mutations (RAMs) is impor-
tant, as this is likely to influence the extent of treatment and
future treatment options.1–3
Since its approval in 2006, a wealth of clinical trial data
and clinical experience has been generated for boosted dar-
unavir (DRV), demonstrating its durable virologic response,
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high genetic barrier to resistance, and long-term safety in a
broad range of patients from ART-naive to highly treatment
experienced.4–11 The once-daily, single-tablet regimen
(STR) of darunavir/cobicistat/emtricitabine/tenofovir alafe-
namide (D/C/F/TAF) 800/150/200/10 mg is approved in the
United States, Europe, and Canada12,13 and is being investi-
gated in two international, randomized Phase III trials,
AMBER in ART-naive adults10 and EMERALD in ART-
experienced, virologically suppressed adults living with
HIV-1.11 D/C/F/TAF had noninferior efficacy versus D/C
plus emtricitabine/tenofovir disoproxil fumarate (F/TDF)
(week 48 virologic response, viral load [VL] <50 copies/mL:
91.4% vs. 88.4%, respectively; FDA-snapshot analysis) in
AMBER10 and versus boosted protease inhibitor (bPI) +
F/TDF for the primary efficacy outcome of protocol-defined
virologic rebound (PDVR) cumulative through week 48 in
EMERALD (D/C/F/TAF: 2.5% vs. bPI + F/TDF: 2.1%).11
Week 48 virologic failure (VF, FDA snapshot; VL ‡50
copies/mL) was 0.8% versus 0.5%, respectively, and viro-
logic response was 94.9% versus 93.7%.11 Current treatment
guidelines include DRV and cobicistat combined with two
nucleoside or nucleotide analog reverse transcriptase inhib-
itors (N(t)RTIs), or administered as the D/C/F/TAF STR, as a
recommended treatment option,2 or recommended in certain
clinical situations, such as for those patients who may have
uncertain adherence, those who require a regimen with a high
genetic barrier to resistance, or those patients who may not
have resistance results available.1,3
We report HIV-1 resistance data in participants with
protocol-defined virologic failure (PDVF) in AMBER and in
EMERALD (participants with PDVR). In addition, HIV-1
proviral DNA from baseline samples (VL <50 copies/mL)
was retrospectively analyzed to assess the prevalence of ar-
chived RAMs in participants with prior VF or PDVR, who
were most likely to have baseline resistance, in EMERALD.
Methods
AMBER and EMERALD study designs and participants
Detailed methods for the international, multicenter, Phase III,
randomized, active-controlled noninferiority trials, AMBER
(TMC114FD2HTX3001; NCT02431247)10 and EMERALD
(TMC114IFD3013; NCT02269917),11 have been reported
previously.
AMBER (double-blind) included ART-naive adults with a
screening plasma VL ‡1,000 copies/mL, CD4+ cell count
>50 cells/mm3, and HIV-1 virus with genotypic sensitivity to
DRV, emtricitabine, and tenofovir. EMERALD (open-label)
included ART-experienced, virologically suppressed adults
(VL <50 copies/mL for ‡2 months before screening; one 50 £
VL <200 copies/mL within 12 months before screening al-
lowed) while on a stable bPI regimen (DRV/ritonavir or DRV/
cobicistat once daily, atazanavir/ritonavir or atazanavir/
cobicistat once daily, or lopinavir/ritonavir twice daily) +
F/TDF regimens for ‡6 months. Patients with prior experi-
ence with multiple antiretrovirals and prior VF were eligible
for study participation, provided they had no previous VF on
DRV-based regimens and absence of DRV RAMs,14 if his-
torical genotypes were available. No restriction was placed
on the presence of emtricitabine or tenofovir RAMs or any
other RAMs.
The primary outcome of both studies was to demonstrate
noninferior efficacy of D/C/F/TAF 800/150/200/10 mg once
daily compared with the control arm (bPI + F/TDF 200/
300 mg fixed-dose combination [FDC] in EMERALD or D/C
800/150 mg FDC + F/TDF 200/300 mg FDC in AMBER) at
week 48. Patients continued receiving D/C/F/TAF beyond
week 48, provided they consented and continued to derive
benefit as assessed by the investigator. Primary outcome
measures were the proportion of participants with VL <50
copies/mL (virologic response rate) by the FDA-snapshot
analysis at week 48 (AMBER) or PDVR (confirmed VL ‡50
copies/mL or premature discontinuations, irrespective of
reason with last VL ‡50 copies/mL) cumulative through
week 48 (EMERALD). The FDA-snapshot virologic re-
sponse and VF rate (VL ‡50 copies/mL) were also assessed
as efficacy endpoints in EMERALD.
Virology assessments
In both studies, plasma HIV-1 RNA was quantified at
screening, baseline, weeks 2, 4, 8, and 12, and every 12 weeks
thereafter with the COBAS AmpliPrep/COBAS TaqMan
HIV-1 Test V2.0 (Roche Diagnostics, Basel, Switzerland).
Standard resistance testing was done when HIV-1 RNA was
‡400 copies/mL.
ART-naive participants (AMBER). Genotypic resistance
testing was performed using GenoSure MG (HIV-1 prote-
ase [PR]/reverse transcriptase [RT] genotype assay; Mono-
gram Biosciences, South San Francisco, CA) at screening.
Genotypic and phenotypic testing was performed using Phe-
noSense GT (combined HIV-1 PR/RT genotype/phenotype)
postbaseline in participants with PDVF with VL ‡400 cop-
ies/mL at failure (preferably confirmed, or at unconfirmed)
or at later time points.10 PDVF was defined as virologic
nonresponse (VL <1 log10 reduction from baseline and ‡50
copies/mL at week 8, confirmed at next visit) or virologic
rebound (confirmed VL ‡50 copies/mL after confirmed,
consecutive VL <50 copies/mL or confirmed VL >1 log10
increase from the nadir) and/or viremia at the final time point
(VL ‡400 copies/mL at study endpoint or study discontinu-
ation after week 8).
Deep sequencing using NGS GenoSure MG (Illumina
MiSeq; codon variants >1%) was performed retrospectively
on samples from participants with HIV-1 viruses that showed
emerging resistance-associated mutations.
Virologically suppressed ART-experienced partici-
pants (EMERALD). Postbaseline HIV-1 PR and RT geno-
typic resistance testing was performed using GenoSure MG
for participants with PDVR (confirmed VL ‡50 copies/mL or
single unconfirmed last on-treatment HIV-1 RNA ‡50 cop-
ies/mL at premature discontinuation) and who had a VL ‡400
copies/mL at failure (preferably confirmed, or at uncon-
firmed) or at later time points, including participants who
discontinued with a last single VL ‡400 copies/mL.
EMERALD included virologically suppressed adults, and
therefore no standard resistance testing could be performed
on screening or baseline samples. HIV-1 proviral DNA was
analyzed retrospectively using GenoSure Archive on
baseline samples (VL <50 copies/mL) from participants with
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PDVR or prior VF (i.e., the participants most likely to have
HIV-1 viruses with baseline resistance).
Genotypic analysis
Evaluation of screening and treatment-emergent RAMs
(AMBER), or the presence of on-treatment (EMERALD)
RAMs, was based on the PI, N(t)RTI, NNRTI, and integrase
inhibitor International Antiviral Society [IAS]-USA muta-
tion list.14 RAMs were considered developing (emerging) if
they were detected postbaseline but not at screening.
Phenotypic analysis
Assessments of antiretroviral drug susceptibility (predicted
phenotype, ‘‘sensitive,’’ ‘‘resistance possible,’’ or ‘‘resistant’’)
were based on the genotype and applied algorithms (GenoSure
MG or GenoSure Archive) or on the true phenotype, expressed
as the fold change (FC) in the 50% effective concentration in
cell-based assays (EC50) below/equal or above, respectively,
the lower clinical cutoff (when available) or biological cutoff
(otherwise) for the PhenoSense GT report.
Results
ART-naive participants (AMBER)
Baseline characteristics. Overall, 18% of participants
had HIV-1 VL ‡100,000 copies/mL, and median baseline
CD4+ count was 453 cells/mm.3,10 A majority of participants
were infected with HIV-1 subtype B (71%).
As depicted by the protocol at screening, all enrolled
participants had HIV-1 viruses sensitive to DRV, em-
tricitabine, and tenofovir based on the genotype report. As
expected in a treatment-naive population, few participants
had viruses with ‡1 primary PI RAMs (2%) or ‡1 DRV
RAMs (1%) (Table 1). No participants had HIV-1 with ‡3
DRV RAMs, which is correlated with DRV resistance.15
Secondary PI RAMs were observed in HIV-1 of almost all
participants (98%), reflecting the polymorphic nature of these
mutations. NNRTI and N(t)RTI RAMs were detected in HIV-
1 of 16% and 5% of participants, respectively, with K103N
and polymorphic E138E/A mutation being the most prevalent
NNRTI RAMs (both 4%) and A62A/V (3%) the most prev-
alent N(t)RTI RAM (Table 1). No RAMs related to em-
tricitabine or tenofovir were detected.
Subgroup analyses showed that there was no effect of HIV-
1 subtype (B, non-B), presence of baseline primary PI and/or
DRV RAMs, or N(t)RTI RAMs, NNRTI RAMs, M184I/V,
and number of primary PI RAMs on virologic response at
week 48 (FDA snapshot) (data not shown). Of the seven
participants with viruses harboring a DRV RAM at screening
(three in the D/C/F/TAF arm and four in the control arm), six
had virologic response at week 48 and one discontinued due
to other reasons with last available VL <50 copies/mL (FDA
snapshot).
Postbaseline resistance. Through 48 weeks, 8 (D/C/
F/TAF) and 6 (control) participants had PDVF, with virologic
rebound occurring most frequently (Supplementary Fig. S1).
Table 1. Amber Genotype at Screening
D/C/F/TAF
800/150/200/10mg N = 362
Control regimen
(D/C + F/TDF) N= 363
Total
N = 725
Participants with genotypea at screening N = 361b N= 362b N = 723
‡1 DRV RAMc, n (%) 3 (1) 4 (1) 7 (1)
V11V/A/I/T 3 (1) 3 (1) 6 (1)
L33F 0 1 (<1) 1 (<1)
‡1 primary PI RAMc, n (%) 7 (2) 8 (2) 15 (2)
M46M/I/L 0 3 (1) 3 (<1)
Q58Q/E 4 (1) 4 (1) 8 (1)
V82L 1 (<1) 0 1 (<1)
L90M 2 (1) 1 (<1) 3 (<1)
‡1 secondary PI RAM, n (%) 354 (98) 354 (98) 708 (98)
‡1 N(t)RTI RAMc, n (%) 18 (5) 16 (4) 34 (5)
M41M/L 3 (1) 2 (1) 5 (1)
A62A/V 10 (3) 11 (3) 21 (3)
D67N 2 (1) 1 (<1) 3 (<1)
K70K/R 0 1 (<1) 1 (<1)
V75I 1 (<1) 0 1 (<1)
L210W 2 (1) 1 (<1) 3 (<1)
K219Q 2 (1) 1 (<1) 3 (<1)
‡1 NNRTI RAMc, n (%) 55 (15) 63 (17) 118 (16)
V90I 9 (2) 9 (2) 18 (2)
K103N 12 (3) 14 (4) 26 (4)
V106I 7 (2) 11 (3) 18 (2)
E138E/A 12 (3) 16 (4) 28 (4)
V179D 4 (1) 2 (1) 6 (1)
aGenoSure MG.
bOne participant in each arm had failed screening genotypes and were enrolled based on local genotypes.
cIAS-USA mutations16; all observed single and mixture of mutations were concatenated by RAM position.
D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide once daily; Control regimen (D/C + F/TDF), darunavir/cobicistat
plus emtricitabine/tenofovir disoproxil fumarate once daily; DRV, darunavir; RAM, resistance-associated mutation; PI, protease inhibitor;
N(t)RTI, nucleos(t)ide analog reverse transcriptase inhibitor; NNRTI, non-nucleoside analog reverse transcriptase inhibitor.
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Paired screening and postbaseline on-treatment genotypes
were available for seven and two participants, respectively
(Table 2).
No DRV, primary PI, or tenofovir RAMs emerged in HIV-
1 of any participant (Table 2).
The N(t)RTI RAM M184I/V, conferring phenotypic re-
sistance to emtricitabine (FC in EC50 = 56) and lamivudine
(FC = 143), but retaining sensitivity to abacavir, stavudine,
tenofovir, and zidovudine, was identified at week 36 post-
PDVF by Sanger sequencing in only one participant receiv-
ing D/C/F/TAF. M184V was detected pretreatment at
screening by deep sequencing as a minority variant (9%). At
week 12 only the wild-type genotype was detected, and at
week 36, M184I (32%) and M184V (67%) were detected.
This participant had HIV-1 virus with transmitted NNRTI
(efavirenz [FC= 7]/nevirapine [FC= 39]) resistance due to the
presence of K103N at screening. This participant was dis-
continued from the study due to noncompliance after the week
48 database lock. Further testing showed that the observed DRV
plasma concentrations for this participant were low (ranging
from 32.0 to 192 ng/mL, except at week 4 [1,440 ng/mL]) and
much lower than the anticipated DRV steady-state predose
plasma concentration for this participant (*692 ng/mL), which
could be an indication that the participant did not take the
medication regularly as recommended.
All other participants had virus that remained susceptible
to all drugs in the treatment regimens based on genotyp-
ic/phenotypic assessments (PhenoSense GT assay).
One participant in the D/C/F/TAF arm had HIV-1 that de-
veloped the secondary PI RAM I62I/V. Three participants in
the D/C/F/TAF arm and two participants in the control arm,
none of whom met the definition of PDVF, had postbaseline
off-treatment genotype data just after discontinuation (Table 2).
One of the three participants in the D/C/F/TAF arm had virus
with an emerging secondary PI RAM I64I/L/M. As expected,
these secondary PI RAMs had no effect on PI susceptibility.
Virologically suppressed ART-experienced
participants (EMERALD)
Baseline characteristics. Most participants received
DRV/ritonavir or DRV/cobicistat at screening. Median time
since diagnosis was 9.26 years (interquartile range 4.22–
18.12 years).11
Of 1,141 participants, 664 (58%) had received ‡5 previous
antiretrovirals (including screening ART and PI booster
counted as a separate antiretroviral) and 312 (27%) had re-
ceived ‡8 previous antiretrovirals; 472 (41%) had received
‡2 PIs, 474 (42%) ‡3 N(t)RTIs, 340 (30%) ‡1 NNRTI, and
63 (6%) ‡1 integrase inhibitor.
In total, 169 (15%) participants had previous antiretroviral
VF (80 [7%] participants on a PI, 130 [11%] on an N(t)RTI, 74
[6%] on an NNRTI, and 10 [1%] on an integrase inhibitor).
One participant who had HIV-1 with a V11I DRV RAM,
which was a protocol deviation, reported on a historical ge-
notype, was randomized and had a virologic response
throughout the study until week 36, after which the partici-
pant was lost to follow-up.
Archived baseline resistance. HIV-1 proviral DNA from
baseline samples from all participants with prior VF
(N = 169) or with PDVR (N = 27) (i.e., the subgroup most
likely to have baseline resistance) was analyzed.
In the subgroup of all EMERALD participants with pre-
vious VF and genoarchive data (N = 140; 98 D/C/F/TAF and
42 bPI + F/TDF), 4% (n = 6; 4 D/C/F/TAF and 2 bPI +
Table 2. Amber and Emerald: Postbaseline Resistance Through Week 48
Study ART
Participants,
N
Participants
with PDVF,
n (%)
PDVF
participants with
postbaseline
genotype
data, n (%)
Non-PDVF
participants with
postbaseline
genotype
data, n (%)
Participants with ‡1
RAMa postbaselineb, n (%)
Reverse
transcriptase Protease
FTC
or TFV
Primary
PI or DRV
AMBER D/C/F/TAF 362 8 (2) 7 (2) 3 (1) M184I/Vc; n5 1 0
Control regimen
(D/C + F/TDF)
363 6 (2) 2 (1) 2 (1) 0 0
EMERALD D/C/F/TAF 763 19 (2) 1e (<1) 2f (<1) 0 0
Control regimen
(bPId + F/TDF)
378 8 (2) 3g (1) 0 0 0
Total D/C/F/TAF 1125 27 (2) 8 (1) 5 (<1) 1 (<1) 0
All data from the DCFTAF groups are bolded.
aIAS-USA 2015 mutation list16; all observed single and mixture of mutations were concatenated by RAM position.
bAt unconfirmed or confirmed virologic failure or later time point(s).
cConferring phenotypic resistance to emtricitabine and lamivudine, but retaining sensitivity to abacavir, tenofovir, stavudine, and
zidovudine; this participant had HIV-1 virus with transmitted efavirenz and nevirapine resistance shown by the presence of K103N at
screening; MI84V was detected by deep sequencing (9%) at screening.
dAt screening, 266 participants were on boosted DRV (n = 202 DRV/ritonavir; n = 64 DRV/cobicistat), 82 on boosted atazanavir (n = 81
atazanavir/ritonavir; n= 1 atazanavir/cobicistat), and 30 on lopinavir/ritonavir.
eOne rebounder in the D/C/F/TAF arm had an N(t)RTI thymidine analog-associated mutation (TAM), D67D/N.
fOne of these participants had a K103K/N NNRTI RAM conferring resistance to efavirenz and nevirapine.
gOne rebounder in the control arm had an NNRTI RAM, E138E/G, conferring resistance to rilpivirine; this mutation was not related to
any of the study drugs and was probably related to previous ART use.
ART, antiretroviral treatment; PDVF, protocol-defined virologic failure; RAM, resistance-associated mutation; FTC, emtricitabine; TFV,
tenofovir; bPI, boosted protease inhibitor; DRV, darunavir; D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide; F/TDF,
emtricitabine/tenofovir disoproxil fumarate.
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Table 3. Emerald: Prevalence of Baseline RAMS in HIV-1 Proviral DNA for Participants
with Previous Virologic Failure
D/C/F/TAF
800/150/200/10mg N = 763
Control regimen
(bPI + F/TDF) N= 378 Total N = 1,141
Participants with previous VF, N 116 53 169
Participants with previous VF and
genoarchivea data at baseline, Nb
98 42 140
Genotypic Susceptibility, n (%):
All PIs 80 (82) 36 (86) 116 (83)
Boosted ATV 91 (93) 40 (95) 131 (94)
Boosted DRV 98 (100) 42 (100) 140 (100)
Boosted LPV 94 (96) 40 (95) 134 (96)
All N(t)RTIs 53 (54) 19 (45) 72 (51)
FTC 62 (63) 21 (50) 83 (59)
TFV 76 (78) 30 (71) 106 (76)
All NNRTIs 56 (57) 29 (69) 85 (61)
All INIs 86 (88) 39 (93) 125 (89)
DTG 97 (99)c 41 (98)c 138 (99)
EVG 89 (91) 40 (95) 129 (92)
RTG 86 (88) 39 (93) 125 (89)
‡1 DRV RAMsd, n (%) 4e (4) 2 (5) 6 (4)
L33L/F 0 1 (2) 1 (1)
T74T/P 0 1 (2) 1 (1)
L76L/V 1 (1) 0 1 (1)
I84I/V 4 (4) 0 4 (3)
‡1 primary PI RAMsd, n (%) 20 (20) 7 (17) 27 (19)
D30D/N 4 (4) 0 4 (3)
M46M/I/L 8 (8) 5 (12) 13 (9)
I50I/L 0 1 (2) 1 (1)
Q58Q/E 0 1 (2) 1 (1)
T74T/P 0 1 (2) 1 (1)
L76L/V 1 (1) 0 1 (1)
V82V/A/T 1 (1) 2 (5) 3 (2)
I84I/V 4 (4) 0 4 (3)
N88N/S 2 (2) 0 2 (1)
L90L/I/M 8 (8) 3 (7) 11 (8)
‡1 N(t)RTI RAMs, n (%) 46 (47) 23 (55) 69 (49)
‡1 tenofovir RAMsd, n (%) 4 (4) 1 (2) 5 (4)
K65K/R 4 (4) 0 4 (3)
K70K/D/E/N 0 1 (2) 1 (1)
‡1 TAMsd,f n (%) 34 (35) 14 (33) 48 (34)
M41M/L 18 (18) 8 (19) 26 (19)
D67D/N 10 (10) 7 (17) 17 (12)
K70K/R 18 (18) 6 (14) 24 (17)
L210L/W 9 (9) 3 (7) 12 (9)
T215A/C/D/E/F/G/I/L/N/S/T/Y 20 (20) 12 (29) 32 (23)
K219K/E/Q 11 (11) 4 (10) 15 (11)
‡1 emtricitabine RAMsd, n (%) 35 (36) 18 (43) 53 (38)
K65K/R 4 (4) 0 4 (3)
M184M/I/V 31 (32) 18 (43) 49 (35)
‡1 NNRTI RAMs, n (%) 44 (45) 14 (33) 58 (41)
V90V/I 5 (5) 3 (7) 8 (6)
A98A/G/S 5 (5) 1 (2) 6 (4)
L100L/I 2 (2) 0 2 (1)
K101K/E/P/Q/T 7 (7) 1 (2) 8 (6)
K103K/N/R/S 19 (19) 6 (14) 25 (18)
V106V/A/I 3 (3) 1 (2) 4 (3)
V108V/I/M 6 (6) 1 (2) 7 (5)
E138E/A/G/K/P/Q/R 13 (13) 1 (2) 14 (10)
V179V/A/F/I/T 2 (2) 0 2 (1)
Y181Y/C 8 (8) 3 (7) 11 (8)
Y188Y/H/L 3 (3) 0 3 (2)
(continued)
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F/TDF) had viruses with DRV RAMs, 4% with tenofovir
RAMs (n = 5) (Table 3), and 21% with ‡3 thymidine analog-
associated mutations (TAMs) (n = 29). Emtricitabine RAMs
were seen in 38% (n = 53), mainly at RT position 184 (35%)
(Table 3). Predicted phenotype showed that 100% of partic-
ipants had HIV-1 susceptible to DRV, 59% to emtricitabine,
and 76% to tenofovir; 83% to all PIs, 51% to all N(t)RTIs,
and 61% to all NNRTIs (Table 3). All these participants with
virus harboring archived DRV, emtricitabine, and tenofovir
resistance achieved virologic response (FDA snapshot) at
week 48 or at last on-treatment VL.
In the subgroup of participants with PDVR and genoarc-
hive data (n = 24), none had HIV-1 with archived RAMs to
DRV, emtricitabine, or tenofovir (Table 4). Also no primary
PI RAMs nor TAMs were observed.
Postbaseline resistance. In EMERALD, as there were
few participants with PDVR throughout 48 weeks (19/763
D/C/F/TAF arm and 8/378 control arm), few samples were
eligible for postbaseline genotyping (participants whose VL
rebounded with VL ‡400 copies/mL at failure or at later
time points or at discontinuation). Only three participants in
the D/C/F/TAF arm and zero participants in the control arm
had virologic rebound using the VL ‡200 copies/mL
threshold. One participant whose VL rebounded in the
D/C/F/TAF arm and three participants that rebounded in the
Table 3. (Continued)
D/C/F/TAF
800/150/200/10mg N= 763
Control regimen
(bPI + F/TDF) N = 378 Total N= 1,141
G190G/A/R/S 8 (8) 4 (10) 12 (9)
H221H/Y 1 (1) 1 (2) 2 (1)
P225P/H 1 (1) 1 (2) 2 (1)
M230M/L 0 1 (2) 1 (1)
‡1 Primary INI RAMs, n (%) 5 (5) 1 (2) 6 (4)
T66T/I 2 (2) 0 2 (1)
Q148Q/H/R 1 (1) 1 (2) 2 (1)
N155N/H 2 (2) 0 2 (1)
aGenoSure Archive.
bDenominator for the prevalence of baseline RAMs.16
cTwo participants showed possible resistance to DTG and full resistance to RTG and EVG (integrase inhibitor RAMs: G140S, Q148H
and G140A, Q148R) on the genotype report. Both participants had previously virologically failed on RTG.
dObserved single and mixture of mutations were concatenated by RAM position.
eIn one participant, 2 DRV RAMs were observed (I84I/V and L76L/V).
fThymidine analog-associated mutations (TAMs): M41L, D67N, K70R, L210W, T215Y/F, K291Q/E.16,17
Tenofovir resistance is associated with the presence of ‡3 TAMs, inclusive of either M41L or L210W.
D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide once daily; Control regimen (bPI + F/TDF), boosted protease
inhibitor plus emtricitabine/tenofovir disoproxil fumarate once daily (At screening, 266 participants were on boosted DRV [n = 202
DRV/ritonavir; n = 64 DRV/cobicistat], 82 on boosted ATV [n = 81 ATV/ritonavir; n = 1 ATV/cobicistat], and 30 on LPV/ritonavir)
VF, virologic failure; PI, protease inhibitor; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; N(t)RTI, nucleos(t)ide analog reverse
transcriptase inhibitor; FTC, emtricitabine; TFV, tenofovir; NNRTI, non-nucleoside analogue reverse transcriptase inhibitor; INI, integrase
inhibitor; DTG, dolutegravir; EVG, elvitegravir; RTG, Raltegravir; RAM, resistance-associated mutation.
Table 4. Emerald: Prevalence of Baseline RAMS in HIV-1 Proviral DNA for Participants with PDVR
D/C/F/TAF
800/150/200/10mg N = 763
Control regimen
(bPI + F/TDF) N= 378
Total
N= 1,141
Participants with PDVR, N 19 8 27
Participants with PDVR and genoarchivea
data at baseline, Nb
17 7 24
Genotypic Susceptibility, n (%)
All PIs 16c (94) 7 (100) 23c (96)
All N(t)RTIs 17 (100) 7 (100) 24 (100)
All NNRTIs 13 (76) 7 (100) 20 (83)
All INIs 17 (100) 7 (100) 24 (100)
‡1 DRV RAMs/primary PI RAMs, n (%) 0 0 0
‡1 tenofovir RAMs, n (%) 0 0 0
‡1 TAMs n (%) 0 0 0
‡1 emtricitabine RAMs, n (%) 0 0 0
aGenoSure Archive.
bDenominator for the prevalence of baseline RAMs.16
cOne participant had HIV-1 virus not susceptible to nelfinavir or unboosted atazanavir.
D/C/F/TAF, darunavir/cobicistat/emtricitabine/tenofovir alafenamide once daily; Control regimen (bPI + F/TDF), boosted protease
inhibitor plus emtricitabine/tenofovir disoproxil fumarate once daily (At screening, 266 participants were on boosted DRV [n = 202
DRV/ritonavir; n = 64 DRV/cobicistat], 82 on boosted atazanavir [n = 81 atazanavir/ritonavir; n= 1 atazanavir/cobicistat], and 30 on
lopinavir/ritonavir); PDVR, protocol-defined virologic rebound; PI, protease inhibitor; N(t)RTI, nucleos(t)ide analog reverse transcriptase
inhibitor; NNRTI, non-nucleoside analogue reverse transcriptase inhibitor; INI, integrase inhibitor; DRV, darunavir; RAM, resistance-
associated mutation; TAM, thymidine analog-associated mutation.
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control arm had postbaseline genotypes (Table 2 and Sup-
plementary Fig. S2).
For the four postbaseline PR and RT sequences, the pre-
dicted phenotypic assessment (based on the GenoSure MG
assay) was that all participants had HIV-1 virus susceptible to
all the drugs in the treatment regimen and no DRV, primary
PI, tenofovir, or emtricitabine RAMs were observed
(Table 2).
One participant with PDVR in the D/C/F/TAF arm had
virus with one TAM, D67D/N, and one participant with
PDVR in the control arm had HIV-1 with an NNRTI RAM,
E138E/G, conferring resistance to rilpivirine. Two further
participants in the D/C/F/TAF arm who discontinued at week
12, but whose VL did not rebound (assessed as ‘‘no VL data
in the week 48 window’’ by the FDA-snapshot analysis), had
a genotype at a posttreatment follow-up visit. One of these
participants had virus with a K103K/N NNRTI RAM con-
ferring resistance to efavirenz, which was probably related to
previous use of efavirenz, emtricitabine, and TDF (Atripla).
Discussion
The week 48 analyses of the two investigational Phase III,
randomized, controlled trials showed that the D/C/F/TAF
once-daily STR had a response rate of 91% in ART-naive
participants in AMBER and 95% in virologically suppressed
participants in EMERALD, with VF rates of 4% and 1%,
respectively, and a high genetic barrier to resistance. Through
week 48 in both studies, no treatment-emergent DRV or
primary PI RAMs were observed in the HIV-1 of 1,125
participants receiving D/C/F/TAF, or in 629 participants re-
ceiving boosted DRV in combination with F/TDF in the
control arms. No tenofovir RAM or tenofovir resistance was
observed in either trial. The most common N(t)RTI RAM,
M184I/V (conferring high-level in vitro resistance to em-
tricitabine and lamivudine), was identified post-VF in HIV-1
of only one participant in the D/C/F/TAF arm of AMBER.
However, the presence of M184I/V is not a contraindication
to the use of emtricitabine and lamivudine, because these
RAMs increase tenofovir susceptibility and decrease viral
replication fitness.18 For this participant, M184V was de-
tected in the virus pretreatment by deep sequencing (Illumina
MiSeq) as a minority variant (9%). This participant also had
HIV-1 with transmitted NNRTI (efavirenz/nevirapine) re-
sistance as shown by the presence of K103N at screening.
This participant was potentially nonadherent as indicated by
the low DRV plasma concentrations, which were lower than
the steady-state predose concentration, and the participant
discontinued from the study due to noncompliance.
These results are consistent with those of a previous meta-
analysis of postbaseline resistance among participants in the
DRV 800 mg once-daily dosing arms from seven clinical
Phase II and III studies.9 Only four of 1,686 (0.2%) partici-
pants had viruses that developed postbaseline primary PI
and/or DRV RAMs, and only one of 1,686 (<0.1%) partici-
pant had HIV-1 that lost DRV phenotypic susceptibility after
having previously failed lopinavir/ritonavir. To our knowl-
edge, no participant that has not previously failed another PI
has ever failed with HIV-1 that was phenotypically resistant
to DRV. Only 10 of 1,103 participants from the seven clinical
trials using an N(t)RTI backbone (0.9%) had viruses that
developed ‡1 N(t)RTI RAM, and eight of those had HIV-1
harboring the emtricitabine RAM M184I/V; no tenofovir
RAM or tenofovir resistance was detected. Other studies
investigating F/TAF containing STR regimens showed sim-
ilar results. Two Phase III studies investigating virologically
suppressed participants who switched to rilpivirine/em-
tricitabine/tenofovir alafenamide reported zero and two
M184V RAMs postbaseline out of 43819 and 31620 partici-
pants, respectively. Of 959 virologically suppressed partici-
pants assigned to the elvitegravir/cobicistat/emtricitabine/
tenofovir (E/C/F/TAF) alafenamide arm, one had HIV-1 that
developed M184M/I.21 In two Phase III studies in ART-naive
adults investigating the E/C/F/TAF STR (in total 866 par-
ticipants were in the E/C/F/TAF arm), development of the
M184V/I RAM was observed in HIV-1 of 11 E/C/F/TAF
participants and the K65R/N RAM in viruses of two partic-
ipants.22,23 In Phase III studies of bictegravir, emtricitabine,
and tenofovir alafenamide (B/F/TAF) in ART-naive 24,25 and
virologically suppressed adults,26,27 no treatment emergent
resistance to the components of the treatment regimen were
identified.
In AMBER through week 48, only eight out of 362 ART-
naive participants in the D/C/F/TAF arm and six out of 363 in
the control arm had PDVF, with paired screening and post-
baseline on-treatment genotypes available for seven and two
participants, respectively.10 Similarly, as there were few
participants whose VL rebounded through 48 weeks in
EMERALD, with most participants having low VL values,
samples from only one participant who rebounded in the
D/C/F/TAF arm, and three who rebounded in the control arm
were eligible for post-week 48 HIV-1 genotypic resistance
analysis. Most participants with rebound had resuppressed
VL by week 48 and confirmed rebounds ‡200 copies/mL
occurred in only three participants in the D/C/F/TAF arm and
none in the control arm.11
In EMERALD, exclusion criteria were less restrictive (and
thus participants may be more representative of the real
world) than in other recent switch studies for HIV ART.26–33
While participants in EMERALD were ART experienced,
with 58% of participants having received ‡5 previous anti-
retroviral agents, and 15% had previous VF, few participants
had PDVR cumulative through week 48. Subgroup analyses
by previous antiretroviral use and VF showed no effect on
rebound rates, virologic response, and VF rates by the FDA-
snapshot analysis.11,34 There was no exclusion on the basis of
tenofovir or emtricitabine RAMs. In EMERALD D/C/F/TAF
participants with previous VF (n= 98) at baseline, 37%
(n= 36) had HIV-1 not fully susceptible to emtricitabine and
22% (n= 22) not fully susceptible to tenofovir (based on the
genoarchive assay); baseline archived RAMs to tenofovir
(4 D/C/F/TAF participants) and emtricitabine (35 D/C/F/
TAF participants, mainly 31 with M184I/V) were observed.
Nineteen percent (n = 19) had HIV-1 with ‡3 TAMs, of which
9% (n = 9) had virus with L210W and 18% (n = 18) with
M41L (tenofovir resistance is also associated with the pres-
ence of ‡3 TAMs, inclusive of either M41L or L210W).17
This observed archived resistance did not preclude virologic
response in D/C/F/TAF participants. In participants with
PDVR, none had viruses with archived RAMs to DRV, em-
tricitabine, and tenofovir. The clinical utility of proviral DNA
resistance has yet to be fully established. These next-
generation sequencing genotypic assays that analyze HIV-1
proviral DNA might miss some previous drug resistance
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mutations found in plasma viral RNA and vice versa, and
they should be interpreted with caution.1,35,36
In EMERALD, the only exclusion criterion for presence of
mutations was the presence of ‡1 DRV RAMs if historical
genotypes were available (or if not, previous VF on DRV-based
regimens). This exclusion criterion was introduced in line with
the DRV once-daily indication in ART-experienced virologi-
cally failing participants. Efficacy from a pooled dataset of
studies in highly ART-experienced participants, who had re-
ceived treatment with DRV/ritonavir 600/100 mg twice daily,
was shown to be compromised only in the presence of ‡3 DRV
RAMs in the background of a high number of PI RAMs (me-
dian of 14 or 15, respectively).15 There were three participants
with HIV-1 harboring a DRV RAM (V11I) pre-D/C/F/TAF
treatment in AMBER, all who had virologic response at week
48 (or at discontinuation) by the FDA-snapshot analysis. These
observations are also in line with Lathouwers et al.9 who
showed that of 14 participants who had viruses with a DRV
RAM at baseline and received DRV 800 mg once daily-based
regimens, all achieved virologic response. In EMERALD, in
the subgroup with previous VF or PDVR receiving D/C/F/TAF
with genoarchive data, 4 (all previous VFs) participants had
HIV-1 with archived DRV RAMs (all had viruses harboring
one DRV RAM and one participant had virus with 2 DRV
RAMs) at baseline. All of these 4 participants had virologic
response at week 48 (FDA-snapshot analysis).
D/C/F/TAF may have an important role for treating pa-
tients with uncertain adherence or for rapid initiation in
patients for whom resistance testing results are not yet
available.1,3 Furthermore, D/C/F/TAF does not require HLA
B*5701 screening or hepatitis testing before treatment initi-
ation. All these characteristics suggest D/C/F/TAF is a fea-
sible option in a test and treat setting or for ART-naive
patients, where rapid treatment is justified. D/C/F/TAF is
being evaluated in the first known Phase III trial (single arm;
N = 109) of an STR in a rapid initiation model in the DIA-
MOND study (NCT03227861).37 In the primary intent-to-
treat analysis, 84% of patients (92/109) achieved virologic
response at week 48 (FDA-snapshot analysis).
In conclusion, D/C/F/TAF has a high genetic barrier to
resistance in ART-naive and ART-experienced adults living
with HIV-1, even in those with virus harboring archived
study drug RAMs at baseline. The D/C/F/TAF STR combines
the efficacy and high genetic barrier to resistance of DRV
with the safety advantages of TAF to provide a new option for
people living with HIV-1.
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